Portal de Periódicos da CAPES

The treatment of advanced neuroblastoma. Results of the spanish neuroblastoma study group (SNSG) studies

1995; Elsevier BV; Volume: 31; Issue: 4 Linguagem: Inglês

10.1016/0959-8049(95)00072-q

1879-0852

Victoria Castel, P García-Miguel, Carlos Melero Moreno, Aurora Navajas, S. Navarro, José Manuel Molina, M.D. Badal,

Cancer, Hypoxia, and Metabolism

Abstract The Spanish Neuroblastoma Study Group has conducted a study on advanced neuroblastoma (N-I-87), which included 33 stage III and 60 stage IV neuroblastoma children more than 1 year of age , enrolled between October 1987 and April 1992. They were staged according to Evans and treated with induction chemotherapy (IC) consisting of 3 courses of cyclophosphamide-doxorubicin alternating with 3 of high-dose cisplatin-teniposide. Evaluation after IC and surgery demonstrated an overall response rate of 88% for stage III and 69% for stage IV. In the latter, complete responses and good partial responses were 33 and 14%, respectively. After surgery, children received maintenance chemotherapy (all stage III except 2 and 30 stage IV) or autologous bone marrow transplantation (ABMT) (11 stage IV), the distribution was not randomised. Probability of survival at 5 years was 0.60 ± 0.12 for stage III and 0.24 ± 0.07 for stage IV. A significant difference in survival at 5 years was found between "good responders" and "non-responders" to initial chemotherapy.